4D Molecular Therapeutics Inc
Research 4D Molecular Therapeutics Inc (FDMT) on Bullrun: market cap USD 717.78M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerFDMT
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 717.78M
- Financial periodQ2 2026
- RevenueUSD 3.78M
- Net income-USD 72.94M
- Free cash flow-USD 70.05M
Valuation Snapshot
latest market cap is USD 717.78M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 85.21M | -USD 140.11M | -USD 109.62M | n/a | -2.42 | USD 60.24M | USD 21.41M | USD 505.66M |
| FY2024 | USD 37.00K | -USD 160.87M | -USD 138.37M | n/a | -2.98 | USD 149.34M | USD 24.61M | USD 510.61M |
| FY2023 | USD 20.72M | -USD 100.84M | -USD 78.56M | n/a | -2.58 | USD 249.11M | USD 14.67M | USD 307.83M |
| FY2022 | USD 3.13M | -USD 107.49M | -USD 98.22M | n/a | -3.32 | USD 52.35M | USD 16.12M | USD 231.34M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 717.78M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 432.06M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 255.07M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 866.19M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 719.44M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 707.01M | n/a | n/a | n/a |
About 4D Molecular Therapeutics Inc
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is 4D Molecular Therapeutics Inc's market cap?
4D Molecular Therapeutics Inc's market capitalization is USD 717.78M.
What does 4D Molecular Therapeutics Inc do?
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema.